KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Vir Biotechnology (VIR) Tax Provisions (2018 - 2025)

Vir Biotechnology's Tax Provisions history spans 8 years, with the latest figure at -$137000.0 for Q4 2025.

  • On a quarterly basis, Tax Provisions fell 59.3% to -$137000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $217000.0, a 118.95% increase, with the full-year FY2025 number at $217000.0, up 118.95% from a year prior.
  • Tax Provisions hit -$137000.0 in Q4 2025 for Vir Biotechnology, down from $168000.0 in the prior quarter.
  • Over the last five years, Tax Provisions for VIR hit a ceiling of $403.3 million in Q1 2022 and a floor of -$157.2 million in Q2 2022.
  • Historically, Tax Provisions has averaged $12.3 million across 5 years, with a median of $34500.0 in 2021.
  • The widest YoY moves for Tax Provisions: up 205658.16% in 2022, down 296756.6% in 2022.
  • Tracing VIR's Tax Provisions over 5 years: stood at $20.6 million in 2021, then crashed by 342.48% to -$50.0 million in 2022, then surged by 90.44% to -$4.8 million in 2023, then skyrocketed by 98.2% to -$86000.0 in 2024, then tumbled by 59.3% to -$137000.0 in 2025.
  • Business Quant data shows Tax Provisions for VIR at -$137000.0 in Q4 2025, $168000.0 in Q3 2025, and $170000.0 in Q2 2025.